MA29262B1 - Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 - Google Patents
Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2Info
- Publication number
- MA29262B1 MA29262B1 MA30158A MA30158A MA29262B1 MA 29262 B1 MA29262 B1 MA 29262B1 MA 30158 A MA30158 A MA 30158A MA 30158 A MA30158 A MA 30158A MA 29262 B1 MA29262 B1 MA 29262B1
- Authority
- MA
- Morocco
- Prior art keywords
- diabetes
- prevention
- preparation
- treatment
- rimonabant
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003015 rimonabant Drugs 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
UTILISATION DU RIMONABANT SEUL OU ASSOCIÉ À UN AUTRE PRINCIPE ACTIF, POUR LA PRÉPARATION DE MÉDICAMENTS UTILES DANS LA PRÉVENTION ET LE TRAITEMENT DU DIABÈTE DE TYPE 2 OU DIABÈTE NON INSULINO-DÉPENDANT ET/OU DE SES COMPLICATIONS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0501861A FR2882261B1 (fr) | 2005-02-21 | 2005-02-21 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
| FR0504942A FR2882264A1 (fr) | 2005-02-21 | 2005-05-12 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
| FR0505228A FR2882265B1 (fr) | 2005-02-21 | 2005-05-23 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29262B1 true MA29262B1 (fr) | 2008-02-01 |
Family
ID=36809538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30158A MA29262B1 (fr) | 2005-02-21 | 2007-08-23 | Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP2008530189A (fr) |
| BR (1) | BRPI0608183A2 (fr) |
| CR (1) | CR9293A (fr) |
| EA (1) | EA011618B1 (fr) |
| FR (2) | FR2882264A1 (fr) |
| IL (1) | IL185401A0 (fr) |
| MA (1) | MA29262B1 (fr) |
| MX (1) | MX2007009996A (fr) |
| TN (1) | TNSN07297A1 (fr) |
| TW (1) | TW200640457A (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
-
2005
- 2005-05-12 FR FR0504942A patent/FR2882264A1/fr not_active Withdrawn
- 2005-05-23 FR FR0505228A patent/FR2882265B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-20 TW TW095105631A patent/TW200640457A/zh unknown
- 2006-02-20 EA EA200701781A patent/EA011618B1/ru not_active IP Right Cessation
- 2006-02-20 JP JP2007555669A patent/JP2008530189A/ja not_active Withdrawn
- 2006-02-20 BR BRPI0608183-5A patent/BRPI0608183A2/pt not_active IP Right Cessation
- 2006-02-20 MX MX2007009996A patent/MX2007009996A/es not_active Application Discontinuation
-
2007
- 2007-07-31 TN TNP2007000297A patent/TNSN07297A1/en unknown
- 2007-08-07 CR CR9293A patent/CR9293A/es unknown
- 2007-08-20 IL IL185401A patent/IL185401A0/en unknown
- 2007-08-23 MA MA30158A patent/MA29262B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0608183A2 (pt) | 2009-11-17 |
| EA200701781A1 (ru) | 2007-12-28 |
| MX2007009996A (es) | 2007-10-10 |
| TNSN07297A1 (en) | 2008-12-31 |
| JP2008530189A (ja) | 2008-08-07 |
| FR2882265A1 (fr) | 2006-08-25 |
| IL185401A0 (en) | 2008-08-07 |
| EA011618B1 (ru) | 2009-04-28 |
| CR9293A (es) | 2007-10-01 |
| TW200640457A (en) | 2006-12-01 |
| FR2882264A1 (fr) | 2006-08-25 |
| FR2882265B1 (fr) | 2009-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511477A (pt) | compostos e composições como moduladores de ppar | |
| NO20092639L (no) | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| ATE551996T1 (de) | Behandlung oder prävention von diabetes mit cannabidiol | |
| DE602007004615D1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
| MX2007010560A (es) | Roflumilast para el tratamiento de diabetes mellitus. | |
| EP1756074A4 (fr) | Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes | |
| MA29675B1 (fr) | Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione | |
| CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
| DK1680128T3 (da) | Myo-inositolhexaphosphat til topisk anvendelse | |
| WO2008149802A1 (fr) | Agent anti-fatigue et composition orale comprenant chacun de l'andrographolide en tant que principe actif | |
| BRPI0511527A (pt) | compostos e composições como moduladores de ppar | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| FR2919187B1 (fr) | Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie. | |
| DK1482919T3 (da) | Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes | |
| MA29145B1 (fr) | Préparations pharmaceutiques pour le traitement de la cellulite | |
| MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
| EP2193789A4 (fr) | Utilisation du 3,5-dihydrotoluène ou de ses dérivés dans la préparation de médicaments ou de nourriture fonctionnelle destinés au traitement ou à la prévention de la dépression | |
| TW200503676A (en) | Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
| EP1870099A4 (fr) | Agent protecteur pour une cellule neuronale retinienne comprenant un derive d indazole comme ingredient actif | |
| WO2006108681A3 (fr) | Substances et compositions pharmaceutiques pour l'inhibition de glyoxalases et leur utilisation contre des bacteries | |
| FR2887150B1 (fr) | Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise | |
| MA29263B1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales | |
| SE0203817D0 (sv) | New composition |